Download Full Text (1.1 MB)

Presentation date

Summer 8-10-2022

Faculty Mentor

Dr. Rebecca Oberley-Deegan

Research Mentor

Dr. Rebecca Oberley-Deegan


Prostate cancer is the second leading cause of cancer-related death in men. 10-20% of prostate cancer patients develop castration-resistant prostate cancer (CRPC) The median survival for CRPC patients is 14 months following diagnosis1. CRPC can spread to local tissues like the bladder, lymph nodes, and rectum but will also reach bone through distant metastasis. The metastasis of CRPC proves difficult for clinicians to treat. Redox active compounds can reduce growth and induce death of cancerous cells by the creation of ROS, which cannot be broken down by cancerous cells. This allows treatments like radiation and chemotherapy to be more effective in killing cancer.


Prostate cancer, CRPC, BuOE, tBHQ

BuOE and tBHQ Reduces Growth and Viability of Castrate-Resistant Prostate Cancer